GlassScriptPhysician profile
Charles Glass
NPI 1003219304
$11,246.07
in general payments reported to CMS, 2019-2025
27 companies · $3,275 in 2025
The $3,275 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,096 · 2022: $1,601 · 2023: $2,112 · 2024: $3,162 · 2025: $3,275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,441 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,440.82 |
| Education | $108.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,987.43 | 2021-2025 | |
| Janssen Biotech, INC. | $1,640.52 | 2021-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $1,014.92 | 2021-2025 | |
| Lilly USA, LLC | $751.66 | 2021-2025 | Taltz, Ebglyss, Olumiant |
| E.R. Squibb & Sons, L.L.C. | $737.46 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $725.33 | 2021-2025 | |
| Amgen INC. | $695.20 | 2021-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $472.89 | 2021-2025 | Winlevi, Ilumya, Absorica Ld |
| Leo Pharma INC. | $469.95 | 2022-2025 | Adbry |
| Ucb, INC. | $460.36 | 2021-2025 | Bimzelx, Cimzia |
| Regeneron Healthcare Solutions, INC. | $400.64 | 2021-2025 | Dupixent, Libtayo |
| Galderma Laboratories, L.P. | $333.51 | 2021-2025 | Nemluvio |
| Dermavant Sciences, INC. | $278.39 | 2023-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $229.62 | 2023-2025 | Zoryve |
| Incyte Corporation | $201.62 | 2021-2025 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $151.99 | 2021-2022 | |
| Genentech USA, INC. | $127.58 | 2021-2024 | Xolair, Erivedge |
| Mayne Pharma Commercial LLC | $119.98 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $112.91 | 2024 | Tremfya |
| Pfizer INC. | $103.90 | 2021-2024 | |
| Organon LLC | $78.11 | 2023-2025 | Vtama, Hadlima |
| Mallinckrodt Hospital Products INC. | $50.55 | 2025 | Acthar |
| Vyne Pharmaceuticals INC. | $26.96 | 2021 | |
| Almirall LLC | $23.15 | 2023 | Seysara |
| Allergan, INC. | $20.14 | 2021 | |
| Sandoz INC. | $16.81 | 2024 | Hyrimoz |
| Journey Medical Corporation | $14.49 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Glass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.